Journals / Androloji Bülteni / 2022 / Cilt: 24 - Sayı: 2

Human Papillomavirus (HPV) Infection and current approaches to HPV vaccine

Human Papillomavirus (HPV) Enfeksiyonu ve HPV aşısında güncel yaklaşımlar

Pages
133–139
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review to focus on current approaches in HPV infection and HPV vaccine

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Human papillomavirus (HPV) is one of the most common sexually transmitted infections.
📊
Key Findings & Data:There are three type HPV vaccines including Gardasil, Cervarix and Gardasil 9.
💡
Conclusion & Impact:The aim of this review to focus on current approaches in HPV infection and HPV vaccine
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Human papillomavirus (HPV) is one of the most common sexually transmitted infections. It causes many diseases, including various anogenital and oropharyngeal cancers, especially cervical cancer. Primary protection from HPV includes prophylactic vaccination. There are three type HPV vaccines including Gardasil, Cervarix and Gardasil 9. Around the world, including developed countries, countries have introduced the HPV vaccine into their National Immunization Programs. Current evidences have contributed to achieving the goal of increasing HPV vaccination rates in the prevention of cervical. The aim of this review to focus on current approaches in HPV infection and HPV vaccine

Özet

İnsan papilloma virüsü (HPV-Human papillomavirus) en yaygın cinsel yolla bulaşan enfeksiyonlardan biridir. Servikal kanser başta olmak üzere anogenital ve orofarengeal kanserler dâhil birçok hastalığa HPV neden olmaktadır. Bu hastalıklardan birincil korunma profilaktik HPV aşı uy- gulamalarını içermektedir. Gardasil, Cervarix ve Gardasil 9 olmak üzere üç tip HPV aşısı bulunmaktadır. Dünya genelinde gelişmiş ülkeler dâhil birçok ülke HPV aşılarını ulusal aşılama programlarına dâhil etmeye de- vam etmektedir. Güncel kanıtlar servikal kanserlerin önlenmesi ve HPV aşılama oranlarının artırılmasına katkı sağlamaktadır. Bu derlemede HPV enfeksiyonu ve HPV aşısında güncel yaklaşımlara odaklanılması amaçlanmaktadır.

🔖

Cite This Article

AKALIN, A. (2022). Human Papillomavirus (HPV) Infection and current approaches to HPV vaccine. Androloji Bülteni, Cilt: 24 - Sayı: 2, 133–139. https://ajindex.com/articles/439614

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. de Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology. 2013
  2. 445(1-2):2–10. [CrossRef ] 2. Meites, E, Gee J, Unger E, Markowitz L. Epidemiology and prevention of vaccine-preventable diseases. Centers for Disease Control and Prevention. Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S. (eds.), Human Popillomavirus. 14th ed. Washington DC: Public Health Foundation
  3. p. 165-178. https://www. cdc.gov/vaccines/pubs/pinkbook/downloads/hpv.pdf 3. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014
  4. 41(11):660–4. [CrossRef ] 4. Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA. Incident detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25-65 years. J Infect Dis. 2016
  5. 214(5):665–75. [CrossRef ] 5. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020
  6. 1340–8. [CrossRef ] 6. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019
  7. 68(32):698–702. [CrossRef ] 7. T. C. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı. Türkiye Kanser Kontrol Programı. 1. Baskı. Ankara: 2016. 1–92. https://hsgm.saglik.gov.tr/depo/birimler/ kanser-db/yayinlar/Kitaplar/TURKIYE_KANSER_KONTROL_ PROGRAMI_2016.pdf 8. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü Kanser Daire Başkanlığı. Serviks Kanseri Tarama Programı Ulusal Standartları. https://hsgm.saglik.gov.tr/tr/kanser-tarama- standartlari/listesi/serviks-kanseri-tarama-program%C4%B1- ulusal-standartlar%C4%B1.html 9. International Human Papillomavirus Reference Center. HPV Reference clones, Stockholm: Karolinska Institutet (updated 2021 Sept 06). https://www.hpvcenter.se/human_reference_clones/ 10. Skoulakis A, Fountas S, Mantzana-Peteinelli, M. Pantelidi K. Petinaki E. Prevalence of human papillomavirus and subtype distribution in male partners of women with cervical intraepithelial neoplasia (CIN): a systematic review. BMC Infect Dis. 2019
  8. 19(1):2–11. [CrossRef ] 11. Bruni L, Albero G, Serrano B, Mena M, Gómez D, et al. ICO/ IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Turkey. Summary report 22 October 202